作者
Peter Mohr, Sebastian Haferkamp, Andreas Pinter, Carsten Weishaupt, Margit A Huber, Gerald Downey, Katarina Öhrling, Carmen Loquai, Karly S Louie
发表日期
2019/1
期刊
Advances in therapy
卷号
36
页码范围
101-117
出版商
Springer Healthcare
简介
Introduction
Talimogene laherparepvec is a first-in-class oncolytic immunotherapy for intratumoral injection with proven efficacy and tolerability in patients with unresectable early metastatic melanoma (stage IIIB–IVM1a) in the pivotal phase III OPTiM study. The objective was to characterize melanoma patients treated with talimogene laherparepvec in routine clinical practice in Germany.
Methods
A retrospective chart review was conducted in unresectable stage IIIB–IVM1a melanoma patients. Data on demographics, disease and medical history, and use of talimogene laherparepvec were collected. A survey was also conducted to understand physician treatment decisions.
Results
Data for 27 patients who initiated talimogene laherparepvec between June 2016 and July 2017 were analyzed (median age 68; stage IIIB/C …
学术搜索中的文章
P Mohr, S Haferkamp, A Pinter, C Weishaupt… - Advances in therapy, 2019